275 related articles for article (PubMed ID: 30741481)
1. Daily activity, mood, and quality of life in colorectal cancer patients with chemotherapy-induced peripheral neuropathy: A mediation effect analysis.
Lu LC; Tsay SL; Chang SY; Chen CM; Liu CY
Cancer Med; 2019 Mar; 8(3):963-971. PubMed ID: 30741481
[TBL] [Abstract][Full Text] [Related]
2. Emotional distress and quality of life during folinic acid, fluorouracil, and oxaliplatin in colorectal cancer patients with and without chemotherapy-induced peripheral neuropathy: A cross-sectional study.
Hsu HT; Wu LM; Lin PC; Juan CH; Huang YY; Chou PL; Chen JL
Medicine (Baltimore); 2020 Feb; 99(6):e19029. PubMed ID: 32028414
[TBL] [Abstract][Full Text] [Related]
3. Changes in upper extremity function, ADL, and HRQoL in colorectal cancer patients after the first chemotherapy cycle with oxaliplatin: a prospective single-center observational study.
Tabata A; Kanai M; Horimatsu T; Tsuboyama T; Matsushima K; Kato T
Support Care Cancer; 2018 Jul; 26(7):2397-2405. PubMed ID: 29423680
[TBL] [Abstract][Full Text] [Related]
4. Motor disorders related to oxaliplatin-induced peripheral neuropathy: long-term severity and impact on quality of life.
Balayssac D; Kerckhove N; Selvy M; Pereira B; Gonneau C; Pétorin C; Vimal-Baguet A; Melnikov S; Kullab S; Hebbar M; Bouché O; Slimano F; Bourgeois V; Lebrun-Ly V; Thuillier F; Mazard T; Tavan D; Benmammar KE; Monange B; Ramdani M; Péré-Vergé D; Huet-Penz F; Bedjaoui A; Genty F; Leyronnas C; Pezet D; Martin V
Support Care Cancer; 2024 Jun; 32(7):427. PubMed ID: 38869647
[TBL] [Abstract][Full Text] [Related]
5. Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.
Kuriyama A; Endo K
Support Care Cancer; 2018 Apr; 26(4):1051-1059. PubMed ID: 29280005
[TBL] [Abstract][Full Text] [Related]
6. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
[TBL] [Abstract][Full Text] [Related]
7. The association of clinical and patient factors with chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer: secondary analysis of the SCOT trial.
Lemanska A; Harkin A; Iveson T; Kelly C; Saunders M; Faithfull S
ESMO Open; 2023 Dec; 8(6):102063. PubMed ID: 37988949
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin-induced peripheral neuropathy's effects on health-related quality of life of colorectal cancer survivors.
Tofthagen C; Donovan KA; Morgan MA; Shibata D; Yeh Y
Support Care Cancer; 2013 Dec; 21(12):3307-13. PubMed ID: 23903798
[TBL] [Abstract][Full Text] [Related]
9. Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy.
Hung HW; Liu CY; Chen HF; Chang CC; Chen SC
Int J Environ Res Public Health; 2021 May; 18(11):. PubMed ID: 34073174
[TBL] [Abstract][Full Text] [Related]
10. Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy.
Soveri LM; Lamminmäki A; Hänninen UA; Karhunen M; Bono P; Osterlund P
Acta Oncol; 2019 Apr; 58(4):398-406. PubMed ID: 30638100
[TBL] [Abstract][Full Text] [Related]
11. Non-randomized preliminary study of an education and elastic-band resistance exercise program on severity of neuropathy, physical function, muscle strength and endurance & quality of life in colorectal cancer patients experiencing oxaliplatin-induced peripheral neuropathy.
Chen SC; Huang HP; Huang WS; Lin YC; Chu TP; Beaton RD; Jane SW
Eur J Oncol Nurs; 2020 Dec; 49():101834. PubMed ID: 33120223
[TBL] [Abstract][Full Text] [Related]
12. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
Mizrahi D; Park SB; Li T; Timmins HC; Trinh T; Au K; Battaglini E; Wyld D; Henderson RD; Grimison P; Ke H; Geelan-Small P; Marker J; Wall B; Goldstein D
JAMA Netw Open; 2021 Feb; 4(2):e2036695. PubMed ID: 33587134
[TBL] [Abstract][Full Text] [Related]
13. Protective effect of the oral administration of cystine and theanine on oxaliplatin-induced peripheral neuropathy: a pilot randomized trial.
Kobayashi M; Sato R; Komura T; Ichikawa H; Hirashima T; Otake S; Akazawa N; Yazawa T; Abe T; Okada T; Kakita T; Oikawa M; Tsuchiya T
Int J Clin Oncol; 2020 Oct; 25(10):1814-1821. PubMed ID: 32594273
[TBL] [Abstract][Full Text] [Related]
14. Patterns of Patient-Reported Chemotherapy-Induced Peripheral Neuropathy in Colorectal Cancer Survivors.
Teng C; ; Blinman PL; Vardy JL
J Natl Compr Canc Netw; 2022 Dec; 20(12):1308-1315. PubMed ID: 36509075
[TBL] [Abstract][Full Text] [Related]
15. ZeOxaNMulti Trial: A Randomized, Double-Blinded, Placebo-Controlled Trial of Oral PMA-zeolite to prevent Chemotherapy-Induced Side Effects, in particular, Peripheral Neuropathy.
Vitale MG; Barbato C; Crispo A; Habetswallner F; Martino BM; Riccardi F; Maione A; Eisenwagen S; Vitale G; Cartenì G
Molecules; 2020 May; 25(10):. PubMed ID: 32414185
[TBL] [Abstract][Full Text] [Related]
16. Changes in chemotherapy-induced peripheral neuropathy, disturbance in activities of daily living, and depression following chemotherapy in patients with colorectal cancer: A prospective study.
Oh PJ; Lee JR; Kim SK; Kim JH
Eur J Oncol Nurs; 2020 Feb; 44():101676. PubMed ID: 31751847
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-Induced Peripheral Neurotoxicity in Cancer Survivors: Predictors of Long-Term Patient Outcomes.
Battaglini E; Goldstein D; Grimison P; McCullough S; Mendoza-Jones P; Park SB
J Natl Compr Canc Netw; 2021 Jul; 19(7):821-828. PubMed ID: 34340206
[TBL] [Abstract][Full Text] [Related]
18. Systematic review of long-term chemotherapy-induced peripheral neuropathy (CIPN) following adjuvant oxaliplatin for colorectal cancer.
Teng C; Cohen J; Egger S; Blinman PL; Vardy JL
Support Care Cancer; 2022 Jan; 30(1):33-47. PubMed ID: 34410459
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study).
Misawa S; Denda T; Kodama S; Suzuki T; Naito Y; Kogawa T; Takada M; Suichi T; Shiosakai K; Kuwabara S;
BMC Cancer; 2023 Nov; 23(1):1098. PubMed ID: 37951905
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).
Cheng HL; Molassiotis A
Asia Pac J Clin Oncol; 2019 Feb; 15(1):56-62. PubMed ID: 29873180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
